| Name | Title | Contact Details |
|---|
Echo Therapeutics is developing its Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system. A significant consumer (non-regulated) opportunity also exists for Symphony to be used in the fitness, weight loss and personal lifestyle space. Echo also developed its needle-free skin preparation device as a platform technology that allowed for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
Ideomed is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NeuroVision is developing a noninvasive, quick, and inexpensive retinalimaging test for the early detection and diagnosis of Alzheimer`s disease.
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).
Webmedx is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.